Market News & Trends
Metrics Contract Services Begins $10-Million Plant Expansion
Metrics Contract Services recently announced it has commenced construction on the expansion of its novel oral solid dosage manufacturing facility expansion in Greenville, NC. The…
Oculis to Present Significant Corporate & Clinical Development Progress
Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of patients, recently announced that Dr. Marcia…
Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma
Knopp Biosciences LLC recently announced the completion of enrollment in a Phase 2 trial of the oral small-molecule dexpramipexole in patients with moderate-to-severe eosinophilic asthma.…
ARCA biopharma Announces Submission of IND Application
ARCA biopharma, Inc. recently announced it has submitted an Investigational New Drug (IND) application with the US FDA under the Coronavirus Treatment Acceleration Program (CTAP) to…
Gerresheimer Announces New Laboratory & Regulatory Services for Biotech Customers
Gerresheimer recently announced it has added essential laboratory and regulatory services to its broad portfolio of products, solutions, and services for biotech companies. Specialized laboratory…
Arctoris & Syntekabio Form Drug Discovery Research Partnership
Arctoris has recently signed a Memorandum of Understanding with listed Korean company Syntekabio, Inc. to collaborate on drug discovery efforts. The first project under the…
Orasis Raises $30 Million to Advance Clinical Development Program
Orasis Pharmaceuticals recently announced the closing of a $30-million Series C financing. The financing was co-led by new investor Bluestem Capital and returning investor Visionary…
Imanis Life Sciences Presents a First-in-Class Neutralizing Antibody Test for COVID-19
Imanis Life Sciences, LLC recently announced presentations about the development and validation of IMMUNO-COV, the first scalable, quantitative neutralizing antibody test for COVID-19. The company…
Fortress Biotech Announces Initiation of Phase 3 Studies
Fortress Biotech, Inc. recently announced that Caelum Biosciences, Inc., in collaboration with Alexion Pharmaceuticals, Inc., initiated the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase…
Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine
Vaxart, Inc. recently announced the US FDA has completed its review of the company’s Investigational New Drug (IND) application for its Phase 1 clinical trial…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….